

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4295737

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MATTHEW CHUN	09/22/2015
DANIEL EGAN	10/02/2015
RECEIVING PARTY DATA	
Name:	SALK INSTITUTE FOR BIOLOGICAL STUDIES
Street Address:	10010 NORTH TORREY PINES ROAD
City:	LA JOLLA
State/Country:	CALIFORNIA
Postal Code:	92037
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15505532
CORRESPONDENCE DATA	
Fax Number:	(617)310-6001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-310-6224
Email:	bechetn@gtlaw.com
Correspondent Name:	MELISSA HUNTER-ENSOR, PH.D.
Address Line 1:	ONE INTERNATIONAL PLACE
Address Line 2:	GREENBERG TRAURIG, LLP
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	167776.011103/US
NAME OF SUBMITTER:	MELISSA HUNTER-ENSOR, PH.D.
SIGNATURE:	/MELISSA HUNTER-ENSOR, PH.D./
DATE SIGNED:	02/28/2017
Total Attachments: 8	
source=Chun to Salk#page1.tif	
source=Chun to Salk#page2.tif	
source=Chun to Salk#page3.tif	
source=Chun to Salk#page4.tif	

source=Chun to Salk#page5.tif

source=Chun to Salk#page6.tif

source=Chun to Salk#page7.tif

source=Chun to Salk#page8.tif

ASSIGNMENT

We, Matthew Chun and Daniel Egan, both c/o Salk Institute For Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, ("Inventors"), have invented an invention entitled "NOVEL ULK1 INHIBITORS AND METHODS USING SAME," as set forth in an application for Letters Patent of the United States already filed on August 25, 2015, as PCT Patent Application No.: PCT/US2015/046777, designating the United States which claims the benefit of United States Provisional Application Nos. 62/184,212, filed on June 24, 2015 and 62/041,559, filed on August 25, 2014, respectfully;

The subject invention was made as a result of our activities at or on behalf of the Salk Institute for Biological Studies or as a result of our utilization of information, facilities or other resources of the Salk Institute for Biological Studies. The conditions under which said invention was made are such as to entitle the Salk Institute for Biological Studies to the entire right, title, and interest in the invention(s) and the patent application in the United States and its territories and dependencies, and all other countries of the world.

In consideration of our obligations and other valuable consideration, we the undersigned hereby sell, assign, and transfer to the **Salk Institute for Biological Studies** (hereinafter, "Salk Institute"), its successors and assigns, the full and exclusive right, title, and interest in the invention(s) and the patent application throughout the United States of America and its territories and dependencies, and all other countries of the world. This includes an assignment of all non-provisional patent application and any Letters Patent that may be granted on the invention for corresponding non-provisional patent application in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from the provisional patent application as provided for by United States law, the Patent

Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

We authorize and request the issuance of said Letters Patent to the Salk Institute as assignee of the entire right, title, and interest to be held as fully and entirely as the same would have been held by us had this assignment not been made.

We warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of the present assignment.

We also agree upon reasonable request to communicate to the Salk Institute, its representatives, successors, assigns, or agents, any facts known to us respecting the invention(s), and testify in any legal proceedings, sign all lawful papers, execute all non-provisional, divisional, continuing, and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid the Salk Institute, its representatives, successors, assigns, or agents to obtain and enforce proper patent protection for the invention(s) in the United States or any foreign country. These provisions are binding upon our heirs, legal representatives, administrators and assigns.

IN TESTIMONY WHEREOF, the Assignors have signed their names on the
dates indicated.

Dated: 09-22-2015

Matthew Chun
Matthew Chun

Witnessed by: Name Melissa J. Rodgers
Please Print or Type Name

Signature: Melissa J. Rodgers

Dated: _____

Daniel Egan

Witnessed by: Name _____
Please Print or Type Name

Signature: _____

ASSIGNMENT

We, Matthew Chun and Daniel Egan, both c/o Salk Institute For Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, ("Inventors"), have invented an invention entitled "NOVEL ULK1 INHIBITORS AND METHODS USING SAME," as set forth in an application for Letters Patent of the United States already filed on August 25, 2015, as PCT Patent Application No.: PCT/US2015/046777, designating the United States which claims the benefit of United States Provisional Application Nos. 62/184,212, filed on June 24, 2015 and 62/041,559, filed on August 25, 2014, respectfully;

The subject invention was made as a result of our activities at or on behalf of the Salk Institute for Biological Studies or as a result of our utilization of information, facilities or other resources of the Salk Institute for Biological Studies. The conditions under which said invention was made are such as to entitle the Salk Institute for Biological Studies to the entire right, title, and interest in the invention(s) and the patent application in the United States and its territories and dependencies, and all other countries of the world.

In consideration of our obligations and other valuable consideration, we the undersigned hereby sell, assign, and transfer to the **Salk Institute for Biological Studies** (hereinafter, "Salk Institute"), its successors and assigns, the full and exclusive right, title, and interest in the invention(s) and the patent application throughout the United States of America and its territories and dependencies, and all other countries of the world. This includes an assignment of all non-provisional patent application and any Letters Patent that may be granted on the invention for corresponding non-provisional patent application in the United States of America and all countries throughout the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from the provisional patent application as provided for by United States law, the Patent

Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

We authorize and request the issuance of said Letters Patent to the Salk Institute as assignee of the entire right, title, and interest to be held as fully and entirely as the same would have been held by us had this assignment not been made.

We warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed at the time of the execution of the present assignment.

We also agree upon reasonable request to communicate to the Salk Institute, its representatives, successors, assigns, or agents, any facts known to us respecting the invention(s), and testify in any legal proceedings, sign all lawful papers, execute all non-provisional, divisional, continuing, and reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid the Salk Institute, its representatives, successors, assigns, or agents to obtain and enforce proper patent protection for the invention(s) in the United States or any foreign country. These provisions are binding upon our heirs, legal representatives, administrators and assigns.

IN TESTIMONY WHEREOF, the Assignors have signed their names on the
dates indicated.


Dated: _____

Matthew Chun

Witnessed by: Name _____
Please Print or Type Name

Signature: _____

Dated: 10-2-2015


Daniel Egan

Witnessed by: Name Xing Zeng 
Please Print or Type Name

Signature: 